Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III infant study of RTS,S/AS01E integrated into the EPI schedule
2011-001508-37Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in malaria and hepatitis B (HBV) comparing RTS,S/AS01E integrated EPI arm with Engerix-B control integrated EPI arm (2 arms). Primary endpoint: Non-inferiority of hepatitis B immune response.
02
Drugs
RTS,Shepatitis B vaccine recombinant
03
Conditions
malariahepatitis B (HBV)
Beyond the preview
Go deeper on 2011-001508-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001508-37.